June 2026
DMT
What June 2026's 14 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, 5-MeO-DMT, then ranked by relevance.
Research on DMT in June 2026 was diverse, covering endogenous functions, pharmacokinetics, biosynthesis, and clinical effects. Evidence for endogenous DMT functions is mixed and contested, with conflicting detection reports and receptor affinity mismatches. A Phase 2b trial found GH001 (inhaled DMT) produced rapid, large antidepressant effects in treatment-resistant depression, independent of prior treatment failures. A small PET study found DMT+harmine increased global brain glucose metabolism by 12.5%, and a PBPK modeling study showed CYP2D6 polymorphisms significantly affect DMT and harmine exposure.
Confidence in the evidence
Low-Moderate- Multiple studies are reviews, pre-clinical, or modeling (e.g., 28179, 28204, 28203), not direct human trials.
- The key clinical trial (28182) is a post-hoc analysis of a Phase 2b trial with only 40 patients, limiting generalizability.
- The PET study (27756, 28209) is small (n=14) and single-blind, with exploratory correlations.
- Evidence on endogenous DMT function is directly conflicting (28179, 28204 vs. 28200).
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. 2026 | narrative review | — | Mixed | Psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, but potential therapeutic applications may exist for carefully selected symptoms in stable patients. |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity 2026 | theoretical review | — | Mixed | Evidence for DMT's role in maintaining neuroplasticity is mixed and contested, with conflicting detection reports and receptor affinity mismatches. |
| Synthesis and BiologicalEvaluation of 4‑Bromo-N,N-dimethyltryptamine(4-Br-DMT): A Synthetic BuildingBlock for Future Analog Development 2026 | pre-clinical (synthesis and animal) | — | No effect | 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT. |
| Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation 2026 | modeling (PBPK) | — | Supports | CYP2D6 polymorphisms significantly impact DMT and harmine pharmacokinetics, with poor metabolizers showing increased exposure (AUC +53.3% for DMT) and ultra-rapid metabolizers showing reduced exposure. |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions 2026 | theoretical review | — | Mixed | Evidence for endogenous DMT functions is mixed and contested, with conflicting detection reports and receptor affinity mismatches. |
| Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases 2026 | pre-clinical (biosynthesis) | — | Supports | Genome-based optimization using CRISPR-associated transposases enabled production of 1.62 g/L DMT in fed-batch bioreactors. |
| DMT use in Cluster Headache: Interim Analysis of an International Survey (S23.003) 2026 | survey (interim analysis) | — | Unclear | A survey on DMT use in cluster headache was carried out; no results are reported in the abstract. |
| GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial. 2026 | post-hoc analysis of RCT | 40 | Supports | GH001 (inhaled DMT) produced rapid, large improvements in depressive symptoms versus placebo, with no meaningful correlation between prior treatment failures and improvement. |
| Brain-body integromics of the ayahuasca experience. 2026 | within-subject integrative study | 20 | Supports | Multilayer integration revealed that experiential dimensions of ayahuasca covaried with circulating DMT and β-carbolines, metabolic alterations, and reconfiguration of brain network connectivity. |
| Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study. 2026 | RCT (single-blind, crossover) | 14 | Supports | DMT+harmine increased global cerebral glucose metabolism by 12.5% versus placebo, with widespread cortical increases, particularly in higher-order brain networks. |
| Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study 2026 | RCT (single-blind, crossover) | 14 | Supports | DMT+harmine increased global cerebral glucose metabolism by 12.5% versus placebo, with widespread cortical increases, particularly in higher-order brain networks. |
Psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, but potential therapeutic applications may exist for carefully selected symptoms in stable patients.
narrative review
Evidence for DMT's role in maintaining neuroplasticity is mixed and contested, with conflicting detection reports and receptor affinity mismatches.
theoretical review
4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.
pre-clinical (synthesis and animal)
CYP2D6 polymorphisms significantly impact DMT and harmine pharmacokinetics, with poor metabolizers showing increased exposure (AUC +53.3% for DMT) and ultra-rapid metabolizers showing reduced exposure.
modeling (PBPK)
Evidence for endogenous DMT functions is mixed and contested, with conflicting detection reports and receptor affinity mismatches.
theoretical review
Genome-based optimization using CRISPR-associated transposases enabled production of 1.62 g/L DMT in fed-batch bioreactors.
pre-clinical (biosynthesis)
A survey on DMT use in cluster headache was carried out; no results are reported in the abstract.
survey (interim analysis)
GH001 (inhaled DMT) produced rapid, large improvements in depressive symptoms versus placebo, with no meaningful correlation between prior treatment failures and improvement.
post-hoc analysis of RCT · Sample size: 40
Multilayer integration revealed that experiential dimensions of ayahuasca covaried with circulating DMT and β-carbolines, metabolic alterations, and reconfiguration of brain network connectivity.
within-subject integrative study · Sample size: 20
DMT+harmine increased global cerebral glucose metabolism by 12.5% versus placebo, with widespread cortical increases, particularly in higher-order brain networks.
RCT (single-blind, crossover) · Sample size: 14
DMT+harmine increased global cerebral glucose metabolism by 12.5% versus placebo, with widespread cortical increases, particularly in higher-order brain networks.
RCT (single-blind, crossover) · Sample size: 14
Points of agreement
- DMT shows potential antidepressant effects in clinical trials (28182).
- DMT+harmine increases brain glucose metabolism (27756, 28209).
- Evidence for endogenous DMT functions is mixed and contested (28179, 28204).
Conflicts
- DMT detection in brain: Barker (2025) reports nM concentrations, while Palner et al. (2026) report DMT below detection limit (28179, 28204).
- The intracellular 5-HT2A receptor finding has not been independently replicated (28179, 28204).
Gaps
- Durability of antidepressant effects beyond 6 months (28182).
- Larger, double-blind, placebo-controlled trials with diverse populations (28182, 27756).
- Direct measurement of dietary DMT gap (28179, 28204).
- Independent replication of intracellular 5-HT2A receptor findings (28179, 28204).
- Results from the cluster headache survey (34140).